He summarised the management of anaplastic lymphoma kinase (ALK)/ROS + NSCLC with crizotinib over the last 10 years, and went on to highlight the early inroads by lorlatinib, a third generation ALK inhibitor. The gene discussed is ALK; the disease is non-small cell lung carcinoma.